Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in <scp>AML</scp> patients
Pierre Péterlin, Camille Debord, Marion Eveillard, Alice Garnier, Amandine Le Bourgeois, Thierry Guillaume, Maxime Jullien, Marie C. Béné, Patrice Chevallier
Abstract
Myeloid Derived Suppressive Cells (MDSC) are capable to suppress innate and adaptive immune responses, thus favouring solid cancer progression. However, little is known about the role of MDSC in acute myeloid leukaemia (AML). In this monocentric prospective study, 73 adult AML patients, eligible for first-line intensive chemotherapy, were included with the aim to study the influence on long-term outcomes of peripheral blood (PB) levels of monocytic (M) MDSC (M-MDSC) assessed by flow cytometry. A percentage of peripheral M-MDSC higher than 0.55% of leukocytes at diagnosis and a decrease of M-MDSC% after induction came out both as independent negative prognostic factors for leukaemia-free and overall survival.